Efficacy of ranibizumab for the treatment of diabetic retinopathy: A protocol for systematic review of randomized controlled trial.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
28
4
2019
pubmed:
28
4
2019
medline:
21
5
2019
Statut:
ppublish
Résumé
Previous clinical trials have reported that ranibizumab can be used to treat diabetic retinopathy (DR) effectively. However, no study has been conducted to evaluate its efficacy for patients with DR systematically. Thus, this study will specifically and systematically assess the efficacy and safety of ranibizumab for DR. Cochrane Library, EMBASE, PUBMED, Web of Science, Google Scholar, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database will be searched from inceptions to the March 20, 2019 for studies related to the topic. This study will only consider publicly released randomized controlled trials for evaluating the effect and safety of ranibizumab for DR. No language restrictions will be imposed for all databases search. Methodological quality of each included trial will be assessed by Cochrane risk of bias tool. Statistical analysis will be performed by Stata 12.0 software. This study will provide recent summary evidence of ranibizumab for DR. Primary outcomes include percentages with retinopathy improvement, and cumulative probabilities for retinopathy worsening. Secondary outcome consist of visual function, best-corrected visual acuities, central subfield thickness, total macular volume, peripheral visual field loss, retinal neovascularization, and adverse events. The findings of this study may provide theoretical basis for clinical practice refer and may benefit more patients with DR.
Sections du résumé
BACKGROUND
BACKGROUND
Previous clinical trials have reported that ranibizumab can be used to treat diabetic retinopathy (DR) effectively. However, no study has been conducted to evaluate its efficacy for patients with DR systematically. Thus, this study will specifically and systematically assess the efficacy and safety of ranibizumab for DR.
METHODS
METHODS
Cochrane Library, EMBASE, PUBMED, Web of Science, Google Scholar, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database will be searched from inceptions to the March 20, 2019 for studies related to the topic. This study will only consider publicly released randomized controlled trials for evaluating the effect and safety of ranibizumab for DR. No language restrictions will be imposed for all databases search. Methodological quality of each included trial will be assessed by Cochrane risk of bias tool. Statistical analysis will be performed by Stata 12.0 software.
RESULTS
RESULTS
This study will provide recent summary evidence of ranibizumab for DR. Primary outcomes include percentages with retinopathy improvement, and cumulative probabilities for retinopathy worsening. Secondary outcome consist of visual function, best-corrected visual acuities, central subfield thickness, total macular volume, peripheral visual field loss, retinal neovascularization, and adverse events.
CONCLUSION
CONCLUSIONS
The findings of this study may provide theoretical basis for clinical practice refer and may benefit more patients with DR.
Identifiants
pubmed: 31027141
doi: 10.1097/MD.0000000000015409
pii: 00005792-201904260-00092
pmc: PMC6831126
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15409Références
Diabetes Metab J. 2018 Oct;42(5):364-376
pubmed: 30362302
Clin Exp Ophthalmol. 2019 Mar;47(2):265-273
pubmed: 30238577
Retina. 2015 Feb;35(2):280-7
pubmed: 25272318
Am J Ophthalmol. 2016 Oct;170:206-213
pubmed: 27523491
JAMA Ophthalmol. 2013 Aug;131(8):1033-40
pubmed: 23807371
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Ophthalmology. 2015 Feb;122(2):367-74
pubmed: 25439595
Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149
pubmed: 30005958
J Ocul Pharmacol Ther. 2015 Feb;31(1):37-42
pubmed: 25244301
JAMA Ophthalmol. 2014 Jul;132(7):889-90
pubmed: 25010170
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Ophthalmologica. 2016;235(1):34-41
pubmed: 26630400
JAMA Ophthalmol. 2013 Mar;131(3):283-93
pubmed: 23370902
JAMA Ophthalmol. 2017 Jun 1;135(6):576-584
pubmed: 28492920
Ophthalmic Surg Lasers Imaging Retina. 2014 Nov-Dec;45(6):521-4
pubmed: 25423631
Br J Ophthalmol. 2002 Apr;86(4):363-5
pubmed: 11914197
Doc Ophthalmol. 2012 Jun;124(3):225-36
pubmed: 22457045
Retina. 2014 Jan;34(1):149-56
pubmed: 23807186
JAMA Ophthalmol. 2016 Aug 1;134(8):888-96
pubmed: 27280850
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Arch Ophthalmol. 2012 Sep;130(9):1145-52
pubmed: 22965590
Bull World Health Organ. 2004 Nov;82(11):844-51
pubmed: 15640920
Arch Ophthalmol. 2009 Dec;127(12):1581-3
pubmed: 20008710
Bull World Health Organ. 2003;81(1):19-27
pubmed: 12640472
Retina. 2018 Jun;38(6):1127-1133
pubmed: 28489694
JAMA Ophthalmol. 2017 Jun 1;135(6):558-568
pubmed: 28448655
Curr Med Chem. 2013;20(26):3226-33
pubmed: 23745551
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Ophthalmology. 2017 Apr;124(4):431-439
pubmed: 28161147